Venous thrombosis and predictors of relapse in eosinophil-related diseases

Autor: Matthieu Groh, Francisco Osorio-Perez, Benjamin Terrier, Aurélie Plessier, Divi Cornec, Julien Rohmer, Marc Vasse, Nathalie Freymond, Mohamed Hamidou, Ruben Benainous, Stanislas Faguer, Alexandre Vallée, Marie-Laure Chabi-Charvillat, Elina Zuelgaray, Felix Ackermann, Jean-Emmanuel Kahn, Guy Meyer, A.C. Desbois, Martin Killian, Valériane Réau, Nicolas Simon, G. Bohelay, Noémie Abisror, Sylvain Le Jeune, Guillaume Lefèvre, Colas Tcherakian, Pierre-Emmanuel Rautou, Kewin Panel, Antoine Gaillet, Anne Marchetti
Přispěvatelé: Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Hôpital Foch [Suresnes], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Avicenne [AP-HP], Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Toulouse [Toulouse], CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier de Dax, Centre Hospitalier Universitaire [Grenoble] (CHU), Hémostase, Inflammation, Thrombose (HITH - U1176 Inserm - CHU Bicêtre), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Saclay, Hopital Saint-Louis [AP-HP] (AP-HP), CHU Lille, Hôpital Ambroise Paré [AP-HP], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), HAL-SU, Gestionnaire
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Churg-Strauss Syndrome
030204 cardiovascular system & hematology
Gastroenterology
0302 clinical medicine
Recurrence
Hypereosinophilic Syndrome
Eosinophilic
Eosinophilia
Venous Thrombosis
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology
Leukemia
Multidisciplinary
Portal Vein
Hypereosinophilic syndrome
Middle Aged
3. Good health
Pulmonary embolism
Venous thrombosis
Treatment Outcome
medicine.anatomical_structure
Medicine
Female
medicine.symptom
Eosinophilic vasculitis
Granulomatosis with polyangiitis
Adult
medicine.medical_specialty
Science
Article
03 medical and health sciences
Medical research
Internal medicine
medicine
Humans
Aged
Retrospective Studies
mRNA Cleavage and Polyadenylation Factors
business.industry
Eosinophil
medicine.disease
Eosinophils
030104 developmental biology
Risk factors
Pulmonary Embolism
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Zdroj: Scientific Reports
Scientific Reports, 2021, 11 (1), ⟨10.1038/s41598-021-85852-9⟩
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, Nature Publishing Group, 2021, 11 (1), ⟨10.1038/s41598-021-85852-9⟩
ISSN: 2045-2322
DOI: 10.1038/s41598-021-85852-9⟩
Popis: Eosinophils have widespread procoagulant effects. Eosinophilic cardiovascular toxicity mostly consists of endomyocardial damage or eosinophilic vasculitis, while reported cases of venous thrombosis (VT) are scarce. We aimed to report on the clinical features and treatment outcomes of patients with unexplained VT and eosinophilia, and to identify predictors of relapse. This retrospective, multicenter, observational study included patients aged over 15 years with VT, concomitant blood eosinophilia ≥ 1G/L and without any other moderate-to-strong contributing factors for VT. Fifty-four patients were included. VT was the initial manifestation of eosinophil-related disease in 29 (54%) patients and included pulmonary embolism (52%), deep venous thrombosis (37%), hepatic (11%) and portal vein (9%) thromboses. The median [IQR] absolute eosinophil count at VT onset was 3.3G/L [1.6–7.4]. Underlying eosinophil-related diseases included FIP1L1-PDGFRA-associated chronic myeloid neoplasm (n = 4), Eosinophilic Granulomatosis with Polyangiitis (n = 9), lymphocytic (n = 1) and idiopathic (n = 29) variants of hypereosinophilic syndrome. After a median [IQR] follow-up of 24 [10–62] months, 7 (13%) patients had a recurrence of VT. In multivariate analysis, persistent eosinophilia was the sole variable associated with a shorter time to VT relapse (HR 7.48; CI95% [1.94–29.47]; p = 0.015). Long-term normalization of eosinophil count could prevent the recurrence of VT in a subset of patients with unexplained VT and eosinophilia ≥ 1G/L.
Databáze: OpenAIRE
Externí odkaz: